2 unchanged sentences
directors and officers adopted , modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during
−Removed: the Company's fiscal quarter ended January 31, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of
−Removed: 1934, as amended).
+Added: the Company's fiscal quarter ended July 31, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934,
Exhibit Description
5 unchanged sentences
Certificate of Amendment to the Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed with the Delaware Secretary of State on March 21, 2024 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on March 22, 2024).
−Removed: Certificate of Designations of Preferences and Rights of Series A Preferred Stock, as filed with the Delaware Secretary of State on May 9, 2024 (incorporated by reference to Exhibit 3.1 of the amended Current Report on Form 8-K/A filed with the SEC on May 10, 2024).
Certificate of Designations of Preferences and Rights of Series C Preferred Stock, as filed with the Delaware Secretary of State on February 28, 2025 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on February 28, 2025).
22 unchanged sentences
ALZAMEND NEURO, INC.
−Removed: March 10, 2025
+Added: September 10, 2025
/s/ Stephan Jackman
1 unchanged sentence
Chief Executive Officer (principal executive officer)
−Removed: March 10, 2025
+Added: September 10, 2025
Chief Financial Officer (principal financial and accounting officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.